Table 3.
Drug Name | Target Gene | Mode of Action (Type of Compound) |
Therapy Area | Latest Stage of Development | Company |
---|---|---|---|---|---|
Lademirsen | MIR21 | Expression inhibition (miRNA inhibitor) | Genitourinary system | Phase II | Sanofi |
MTL-CEBPA | CEBPA | Expression activation (saRNA) | Oncology | Phase II | Mina Therapeutics |
remlarsen | MIR29B1 | Expression activation (miRNA mimic) | Dermatology | Phase II | Miragen Therapeutics |